Categories: Health

Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHASKA, Minn., Jan. 16, 2026 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on January 14, 2026, the Lifecore compensation committee approved grants under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of restricted stock unit (“RSU”) awards with respect to an aggregate 1,738 shares of its common stock and stock options for an aggregate 8,775 shares of common stock to two newly hired employees of Lifecore. The RSU award and stock options were granted on January 14, 2026, pursuant to the offer letters between Lifecore and each employee, and as a material inducement to each employee joining Lifecore.

The RSU awards and stock options were approved by Lifecore’s compensation committee and were granted as inducement equity awards in accordance with Nasdaq Listing Rule 5635(c)(4) under the Inducement Plan.

The RSUs will vest and be settled on the third anniversary of the grant date, subject to continued employment. The stock options have an exercise price equal to Fair Market Value (as defined in the Inducement Plan) on the grant date and will vest as to one-third of the shares on the first anniversary of the grant date and as to 1/36th of the shares on each monthly grant date thereafter, subject to continued employment. The stock options have a seven-year term. The RSU award and stock options are each governed by an award agreement and the Inducement Plan.

About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.



GlobeNews Wire

Recent Posts

TBoostExperts.com Announces Availability of 2026 Consumer Report on Testosterone Booster Supplements and Mens Health Supplement Evaluation

NEW YORK,USA, June 27, 2026 (GLOBE NEWSWIRE) -- TBoostExperts.com today announced the availability of its…

6 hours ago

Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreichs Ataxia

June 26, 2026 16:05 ET  | Source: Larimar Therapeutics Webcast on Monday, June 29, 2026,…

6 hours ago

Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease

WILMETTE, Ill., June 26, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”)…

6 hours ago

“UK-India Free Trade Agreement will be India’s most comprehensive agreement so far”: Piyush Goyal at UK-India Week 2026

Capital & Future Frontiers Forum brings together senior ministers, CEOs, investors and innovators to chart…

8 hours ago

From Student to Contributor: Zaggle Founder Announces 4 Crore Upgrade for Kulachi Hansraj Model School

One of the Largest Alumni-Led Contributions in DAV's 132-Year History to Strengthen Education, Infrastructure and…

8 hours ago

HDFC ERGO Highlights the Importance of Comprehensive Car Insurance for Todays Vehicle Owners

Mumbai, Maharashtra, June 27, 2026 (GLOBE NEWSWIRE) -- Today’s vehicle owners face rising repair costs,…

10 hours ago